huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Inclusion Criteria: * Male or female \>= 18 years of age at the time of screening consent INCLUSION CRITERIA FOR SCREENING * Diagnosis of R/R B-cell NHL or ALL as defined below: * Relapsed or refractory B-cell NHL meeting all of the following criteria: * Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; LBCL transformed from any indolent histology; or primary mediastinal B-cell lymphoma (PMBCL) * Prior treatment with an anthracycline and rituximab or another CD20-targeted agent (unless the disease is CD20-negative); transformed DLBCL (tDLBCL) must have failed treatment for DLBCL * At least one of the following: * Refractory disease after frontline chemo-immunotherapy * Not eligible for autologous hematopoietic stem cell transplant (auto-HSCT) * Relapsed or refractory disease after at least 2 lines of therapy or after auto-HSCT * Relapsed or refractory disease after allogeneic hematopoietic stem cell transplant (allo-HSCT) * Relapsed or refractory B-cell ALL (patients with Burkitt's lymphoma/leukemia are not eligible) * All B-ALL patients must have detectable disease by morphology, flow cytometry, cytogenetic analysis (e.g. polymerase chain reaction \[PCR\], fluorescence in situ hybridization \[FISH\], karyotyping) or imaging (e.g. positron emission tomography \[PET\]/computed tomography \[CT\]) or a high likelihood of active disease …